Xine LLC

How Investors May Respond To AbbVie (ABBV) Securing EU Approval For Short-Acting Boey Aesthetic Toxin

In July 2026, Allergan Aesthetics, an AbbVie company, received European Commission approval for Boey (trenibotulinumtoxinE), a rapid-onset, short-duration botulinum neurotoxin serotype E for adults with psychologically impactful moderate to severe glabellar lines, following similar approval in Canada. As the first approved serotype E neurotoxin in Europe with effects beginning as early as eight hours and lasting about two to three weeks, Boey broadens AbbVie’s aesthetics portfolio with a...